Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tito Fojo

Showing results (191-200 of 237) with videos related to

Pageof 24
Sort By:
The Oncologist|July 22, 2024
A review of mitotane in the management of adrenocortical cancerJaydira Del Rivero, Tobias Else, Julie Hallanger-Johnson, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 22, 2015
Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteinsMarianne S Poruchynsky, Edina Komlodi-Pasztor, Shana Trostel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancerJennifer A Low, Suparna B Wedam, James J Lee, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 22, 2007
Ex vivo rapamycin generates apoptosis-resistant donor Th2 cells that persist in vivo and prevent hemopoietic stem cell graft rejectionJacopo Mariotti, Jason Foley, Unsu Jung, et al.
JAMA Network Open|September 28, 2020
Comparison by Race of Conservative Management for Low-Risk and Intermediate-Risk Prostate Cancers in Veterans From 2004 to 2018Ravi B Parikh, Kyle W Robinson, Sumedha Chhatre, et al.
The Oncologist|March 15, 2012
A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumorsRonan J Kelly, Robert W Robey, Clara C Chen, et al.
Annals of Surgical Oncology|February 9, 2011
Liver resection and ablation for metastatic adrenocortical carcinomaR Taylor Ripley, Clinton D Kemp, Jeremy L Davis, et al.
European Journal of Cancer (Oxford, England : 1990)|December 17, 2021
An imaging signature to predict outcome in metastatic colorectal cancer using routine computed tomography scansLaurent Dercle, Binsheng Zhao, Mithat Gönen, et al.
Cancer Drug Resistance (Alhambra, Calif.)|September 20, 2021
Genomic stability at the coding regions of the multidrug transporter gene <i>ABCB1</i>: insights into the development of alternative drug resistance mechanisms in human leukemia cellsKevin G Chen, George E Duran, Mark J Mogul, et al.
Seminars in Oncology|March 14, 2021
Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in VeteransKeith Sigel, Mengxi Zhou, Yeun-Hee Anna Park, et al.
Pageof 24

Showing results (191-200 of 237) with videos related to

Sort By:
Pageof 24
The Oncologist|July 22, 2024
A review of mitotane in the management of adrenocortical cancerJaydira Del Rivero, Tobias Else, Julie Hallanger-Johnson, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 22, 2015
Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteinsMarianne S Poruchynsky, Edina Komlodi-Pasztor, Shana Trostel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancerJennifer A Low, Suparna B Wedam, James J Lee, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 22, 2007
Ex vivo rapamycin generates apoptosis-resistant donor Th2 cells that persist in vivo and prevent hemopoietic stem cell graft rejectionJacopo Mariotti, Jason Foley, Unsu Jung, et al.
JAMA Network Open|September 28, 2020
Comparison by Race of Conservative Management for Low-Risk and Intermediate-Risk Prostate Cancers in Veterans From 2004 to 2018Ravi B Parikh, Kyle W Robinson, Sumedha Chhatre, et al.
The Oncologist|March 15, 2012
A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumorsRonan J Kelly, Robert W Robey, Clara C Chen, et al.
Annals of Surgical Oncology|February 9, 2011
Liver resection and ablation for metastatic adrenocortical carcinomaR Taylor Ripley, Clinton D Kemp, Jeremy L Davis, et al.
European Journal of Cancer (Oxford, England : 1990)|December 17, 2021
An imaging signature to predict outcome in metastatic colorectal cancer using routine computed tomography scansLaurent Dercle, Binsheng Zhao, Mithat Gönen, et al.
Cancer Drug Resistance (Alhambra, Calif.)|September 20, 2021
Genomic stability at the coding regions of the multidrug transporter gene <i>ABCB1</i>: insights into the development of alternative drug resistance mechanisms in human leukemia cellsKevin G Chen, George E Duran, Mark J Mogul, et al.
Seminars in Oncology|March 14, 2021
Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in VeteransKeith Sigel, Mengxi Zhou, Yeun-Hee Anna Park, et al.
Pageof 24